Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Study protocol

SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus

Christopher N Hurt1*, Lisette S Nixon12, Gareth O Griffiths1, Ruby Al-Mokhtar1, Simon Gollins3, John N Staffurth24, Ceri J Phillips5, Jane M Blazeby6 and Tom D Crosby7

Author Affiliations

1 Wales Cancer Trials Unit, School of Medicine, Cardiff University, Cardiff, UK

2 Cardiff NCRI RTTQA group, Department of Medical Physics, Velindre Cancer Centre, Cardiff, UK

3 Department of Clinical Oncology, North Wales Cancer Treatment Centre, Rhyl, UK

4 Institute of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK

5 Swansea Centre for Health Economics, College of Human and Health Sciences, Swansea University, Swansea, UK

6 Surgical Research Unit, School of Social and Community Medicine, University of Bristol, Bristol, UK

7 Velindre Cancer Centre, Cardiff, UK

For all author emails, please log on.

BMC Cancer 2011, 11:466  doi:10.1186/1471-2407-11-466

Published: 28 October 2011

Abstract

Background

Chemoradiotherapy is the standard of care for patients with oesophageal cancer unsuitable for surgery due to the presence of co-morbidity or extent of disease, and is a standard treatment option for patients with squamous cell carcinoma of the oesophagus. Modern regimens of chemoradiotherapy can lead to significant long-term survival. However the majority of patients will die of their disease, most commonly with local progression/recurrence of their tumours. Cetuximab may overcome one of the principal mechanisms of tumour radio-resistance, namely tumour repopulation, in patients treated with chemoradiotherapy.

The purpose of this research is first to determine whether the addition of cetuximab to definitive chemoradiotherapy for treatment of patients with non-metastatic carcinoma of the oesophagus is active (in terms of failure-free rate), safe, and feasible within the context of a multi-centre randomised controlled trial in the UK. If the first stage is successful then the trial will continue to accrue sufficient patients to establish whether the addition of cetuximab to the standard treatment improves overall survival.

Methods/Design

SCOPE1 is a two arm, open, randomised multicentre Phase II/III trial. Eligible patients will have histologically confirmed carcinoma of the oesophagus and have been chosen to receive definitive chemoradiotherapy by an accredited multidisciplinary team including a specialist Upper GI surgeon. 420 patients will be randomised to receive definitive chemoradiotherapy with or without cetuximab using a 1:1 allocation ratio.

During Phase II of the study, the trial will assess safety (toxicity), activity (failure-free rate) and feasibility (recruitment rate and protocol dose modifications/delays) in 90 patients in the experimental arm. If the experimental arm is found to be active, safe, and feasible by the Independent Data Monitoring Committee then recruitment will continue into Phase III. This second stage will recruit a further 120 patients into each arm and compare the overall survival of both groups.

All patients randomised into Phase II will contribute to the Phase III comparison of overall survival. In addition to overall survival, Phase III of the study will also assess toxicity, health related quality of life and cost effectiveness. A detailed radiotherapy protocol and quality assurance procedure has been incorporated into this trial.

Trial registration

ISRCTN: ISRCTN47718479